Emerg Infect DisEIDEmerging Infectious Diseases1080-60401080-6059Centers for Disease Control and Prevention17552100272588306-040310.3201/eid1303.060403DispatchEnvironmental Burkholderia cepacia Complex Isolates from Human InfectionsEnvironmental Burkholderia cepaciaBaldwinAdam*MahenthiralingamEshwar†DrevinekPavel†VandammePeter‡GovanJohn R.§WaineDavid J.*LiPumaJohn J.¶ChiariniLuigi#DalmastriClaudia#HenryDeborah A.**SpeertDavid P.**HoneybourneDavid††MaidenMartin C. J.‡‡DowsonChris G.*Warwick University, Coventry, Wales, United KingdomCardiff University, Cardiff, England, United KingdomUniversiteit Gent, Ghent, BelgiumUniversity of Edinburgh Medical School, Edinburgh, Scotland, United KingdomUniversity of Michigan Medical School, Ann Arbor, Michigan, USAEnte per le Nuove Tecnologie l’Energia e l’Ambiente Casaccia, Rome, ItalyUniversity of British Columbia, Vancouver, British Columbia, CanadaBirmingham Heartlands Hospital, Birmingham, England, United KingdomUniversity of Oxford, Oxford, England, United KingdomAddress for correspondence: Chris G. Dowson, Department of Biological Sciences, University of Warwick, Coventry, CV4 7AL, United Kingdom; email: c.g.dowson@warwick.ac.uk32007133458461
Members of the Burkholderia cepacia complex (Bcc), found in many environments, are associated with clinical infections. Examining diverse species and strains from different environments with multilocus sequence typing, we identified >20% of 381 clinical isolates as indistinguishable from those in the environment. This finding links the natural environment with the emergence of many Bcc infections.
The Burkholderia cepacia complex (Bcc) is a group of closely related gram-negative bacteria comprising at least 9 species (1). They are routinely isolated from the natural environment, where they can have a range of beneficial properties (2). However, these bacteria can also frequently cause fatal infections in vulnerable humans, such as those who have cystic fibrosis (CF). Because Bcc bacteria are not normally carried as commensal organisms, the main sources of infection are considered to be patient-to-patient spread (3,4); hospital settings, including medical devices and contaminated disinfectants; and the environment (5,6). Therefore, although Bcc species may have an important environmental role in agriculture and biotechnology industries, their use also represents a potential clinical risk to susceptible members of the community (7,8). All species of Bcc can be isolated from the environment in differing degrees (2). Similarly, all current Bcc species have been cultured from CF patient sputum (2). Infection control measures have been implemented to reduce patient-to-patient transmission; although effective, these measures have not prevented the emergence of new infection. Thus, the environment could be acting as a constant nonpatient reservoir for infectious Bcc pathogens.
Previous studies have reported the possibility of humans acquiring Bcc directly from natural environments (9,10). The most recent of these studies reported evidence that a B. cenocepacia strain, isolated from soil, was indistinguishable by several typing methods (pulsed-field gel electrophoresis [PFGE] genomic fingerprinting and repetitive extragenic palindromic [rep]–PCR) from isolates of the problematic CF lineage PHDC (10).
The Study
To evaluate how widespread the emergence of environmental isolates as causes of clinical infections may be, we used a highly discriminatory and transportable typing method to study isolates from several large bacterial culture collections. Multilocus sequence typing (MLST) is a relatively new technique based upon unambiguous sequence analysis of several housekeeping genes. Unlike previous methods for Bcc strain typing (10), MLST is not based on banding patterns but instead relies on the robust comparison of DNA sequence information. This process facilitates both the identification and matching of identical clones as well as their evolutionary comparison to closely related strains.
Using a recently validated MLST scheme (11), we analyzed a collection of 381 clinical isolates of all 9 currently reported Bcc species, from 28 countries. A total of 187 distinct sequence types (STs) were identified from clinical isolates within this collection and compared with 233 environmental Bcc isolates (113 STs). We found that 81 clinical isolates (encompassing15 STs) were identical by MLST to a wide range of environmental isolates. This figure represents 21.5% of the clinical isolates examined (for clarity, a subset are shown in the Table; [12]).
MLST analysis of the Burkholderia cepacia strains showing their species, source, and geographic location*
Bcc species
ST
Isolate name
Source
Country
Source of isolate:
Year of isolation
B. cepacia
1
ATCC 17759†
ENV
Trinidad
Soil
1958
1
LMG 14087
NON
UK
Wound
1988
10
ATCC 25416T
ENV
USA
Onion
1948
10
J1050
NON
USA
Human
Before 1983
266
BC20
ENV
USA
Water
–
266
AU6671
NON
U.S.
Wound
–
365
HI-3602
ENV
USA
Soil
–
365
C8509
CF
Canada
Sputum
1999
365
AU3206
CF
USA
Sputum
–
B. multivorans
21
ATCC 17616†
ENV
USA
Soil
Before 1966
21
AU0453
CF
USA
Sputum
–
21
C9140
CF
Canada
Sputum
2000
375
R-20526
ENV
Belgium
River water
2002
375
IST455
CF
Portugal
Sputum
2000
B. cenocepacia IIIA
32
POPR8
ENV
Mexico
Radish
–
32
5–457
CF
Czech Republic
Sputum
2002
32
R-16597
CF
Belgium
Sputum
2001
32
BCC1118
NON
UK
Wound
Before 1994
B. cenocepacia IIIB
37
BC-1
ENV
USA
Maize rhizosphere
–
37
AU2362
CF
USA
Sputum
2000
122
HI-2424
ENV
USA
Soil
–
122
AU1054
CF
USA
CF
–
122
CEP0497
NON
Canada
Leg ulcer
1995
B. stabilis
50
LMG 14294†
CF
Belgium
Sputum
1993
50
R-16919
ENV
Belgium
Industrial
–
50
LMG 14086†
ENVH
UK
Respirator
1970
51
HI-2482
ENV
USA
Shampoo
–
51
ATCC 35254
ENVH
USA
Medical solution
1980
51
CEP0928
ENVH
USA
Albuterol solution
–
51
LMG 14291
CF
Belgium
Sputum
1993
51
LMG 7000
NON
Sweden
Blood
1983
B. vietnamiensis
61
J1702
ENVH
USA
Hospital equipment
–
61
BCC0190
CF
USA
Sputum
–
61
J1712
NON
USA
Wound
–
61
J1738
NON
USA
Wound
–
61
J1742
NON
USA
Wound
–
67
R-20590
ENV
Belgium
River water
2002
67
D0774
CF
Canada
Sputum
2003
B. ambifaria
81
MVP-C2-4
ENV
Italy
Maize rhizosphere
1996
81
BCC0250†
CF
Australia
Sputum
1994
77
AMMDT
ENV
USA
Soil
1985
77
AU0212
CF
USA
Sputum
–
*MLST, multilocus sequence typing; Bcc, B. cepacia complex; ST, sequence type; ENV, isolated from the environment; NON, isolated from a non-cystic fibrosis (CF) patient; CF, isolated from a CF patient; IIIA or IIIB, isolates belonging to B. cenocepacia recA subgroup A or B, respectively; ENVH, isolated from a hospital environment. †, panel strain (12); suprascript T, type strain for species.
The resolution of strain identification offered by MLST is such that different isolates sharing the same ST (genotypically indistinguishable at all 7 loci) are defined as clones of the same strain (e.g., for a group of isolates within this collection, we have further validated this identity by cloning and sequencing up to 10 random fragments of DNA). The 15 STs identified from environmental and clinical sources belonged to 6 different Bcc species (Table): B. cepacia (4 STs), B. multivorans (2 STs), B. cenocepacia (3 STs), B. stabilis (2 STs), B. vietnamiensis (2 STs), and B. ambifaria (2 STs). Three B. cenocepacia STs also belonged to 2 different recA lineages defined within this species: IIIA (1 ST) and IIIB (2 STs).
Conclusions
STs occurring in both clinical and environmental niches were found in 6 of the 9 formally described Bcc; the greatest degree of overlap occurred in B. cepacia and B. stabilis (Figure). The proportion of STs not shared between clinical and environmental isolates varied for each Bcc species we examined. This finding may reflect the few clinical or environmental isolates for that species or high genetic diversity; a larger sample size is needed to find identical matches. Species dominated by clinical STs (>83% of STs) were B. multivorans, B. cenocepacia recA lineage IIIA, and B. dolosa. Those species containing mainly environmental STs (>80%) were B. ambifaria, B. anthina, and B. pyrrocinia (Figure). Although this distribution agrees with findings of previous studies (2), it also reflects the distribution of isolates within the collections from which isolates were obtained.
Proportion of sequence types (STs) within each Burkholderia cepacia complex (Bcc) species from clinical, environmental, or both sources. The bar chart shows the proportion of STs derived from the environment (white), clinical (gray), and both sources (black shading). The total number of STs examined for each B. cepacia species is in parentheses.
Several ST matches between clinical and environmental isolates were of particular interest. MLST ST-10 was shared by B. cepacia J1050, a human isolate cultured in the United States (Cleveland, Ohio) and the type strain for B. cepacia ATCC 25416, isolated from an onion. This evidence of clonality augments the clonal relationship reported earlier (9) between ATCC 25416 and a UK isolate from a CF patient. The B. multivorans IST455 isolated from a CF patient’s sputum in Portugal, as reported in a previous study (13) had the same sequence type (ST-375) as R-20526, which was isolated from the River Schelde in Belgium.
B. cenocepacia recA lineage IIIA isolates with ST-32 (Table) were from 4 independent sources: POPR8 (isolated from a radish in Mexico), BCC1118 (isolated from a UK non-CF patient infection), R-16597 (isolated from a CF patient in Belgium), and 5–457 (isolated from a CF patient in the Czech Republic). ST-32 appears to be a globally distributed, predominantly clinical strain (A. Baldwin, unpub. data). The B. cenocepacia recA lineage IIIB isolates identified as ST-122 (Table) include the PHDC strains, predominant in US CF patients (AU1054) and previously found in US soil (HI-2424) (10), and CEP0497, which was obtained from a leg wound in a non-CF patient in Canada. Together with a recent report of PHDC strains identified in Europe (14), the Canadian isolate in our study adds further weight to the identification of this ST as a globally distributed strain.
MLST analysis of B. stabilis corroborated the high degree of clonality observed by PFGE fingerprint analysis in the original description of this species (15). However, MLST was further able to distinguish 8 STs among the 26 isolates examined, which indicates that MLST may be a more effective method than PFGE for epidemiologic analysis of B. stabilis. This increased resolution adds to the observation that 2 B. stabilis STs are globally distributed and isolated from clinical samples and an array of different niches, including domestic products, medical solutions, industrial process contaminants, and hospital devices.
In summary, >20% of the clinical isolates we examined were indistinguishable by MLST from isolates from environmental sources. This finding suggests that conservation of intrinsic determinants necessary to thrive in environmental niches may confer an ability to colonize susceptible humans. Further work is urgently required to more extensively investigate the emergence of pathogenic members of the Bcc in the natural environment and the risk for infection this may represent.
Suggested citation for this article: Baldwin A, Mahenthiralingam E, Drevinek P, Vandamme P, Govan JR, Waine DJ, et al. Environmental Burkholderia cepacia complex isolates from human infections. Emerg Infect Dis [serial on the Internet]. 2007 Mar [date cited]. Available from http://www.cdc.gov/eid/content/13/3/458.htm
Acknowledgments
We thank Angela Marchbank and Lynne Richardson for technical support. This publication made use of the Bcc multilocus sequence typing website (http://pubmlst.org/bcc/) developed by Keith Jolley and hosted at the University of Oxford.
This work was funded by the Wellcome Trust, grant number 072853. The Trust also funded development of the website.
Dr Baldwin is a postdoctorate research fellow at the University of Warwick on a 3-year project funded by the Wellcome Trust. His main research interests are horizontal gene transfer, pathogenicity islands, evolutionary biology, and epidemiology of bacterial populations.
ReferencesCoenyeT, VandammeP, GovanJR, LiPumaJJTaxonomy and identification of the Burkholderia cepacia complex.J Clin Microbiol2001;39:3427–3610.1128/JCM.39.10.3427-3436.200111574551MahenthiralingamE, UrbanTA, GoldbergJBThe multifarious, multireplicon Burkholderia cepacia complex.Nat Rev Microbiol2005;3:144–5610.1038/nrmicro108515643431GovanJR, BrownPH, MaddisonJ, DohertyCJ, NelsonJW, DoddM, Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.Lancet1993;342:15–910.1016/0140-6736(93)91881-L7686239LiPumaJJ, DasenSE, NielsonDW, SternRC, StullTLPerson-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis.Lancet1990;336:1094–610.1016/0140-6736(90)92571-X1977981HutchinsonGR, ParkerS, PryorJA, Duncan-SkingleF, HoffmanPN, HodsonME, Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis.J Clin Microbiol1996;34:584–78904419OieS, KamiyaAMicrobial contamination of antiseptics and disinfectants.Am J Infect Control1996;24:389–9510.1016/S0196-6553(96)90027-98902114HolmesA, GovanJ, GoldsteinRAgricultural use of Burkholderia (Pseudomonas) cepacia: a threat to human health?Emerg Infect Dis1998;4:221–79621192LiPumaJJ, MahenthiralingamECommercial use of Burkholderia cepacia.Emerg Infect Dis1999;5:305–610221892GovanJRW, BalendreauJ, VandammePBurkholderia cepacia - Friend and foe.ASM News2000;66:124–5LiPumaJJ, SpilkerT, CoenyeT, GonzalezCFAn epidemic Burkholderia cepacia complex strain identified in soil.Lancet2002;359:2002–310.1016/S0140-6736(02)08836-012076559BaldwinA, MahenthiralingamE, ThickettKM, HoneybourneD, MaidenMC, GovanJR, Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex.J Clin Microbiol2005;43:4665–7310.1128/JCM.43.9.4665-4673.200516145124CoenyeT, VandammeP, LiPumaJJ, GovanJR, MahenthiralingamEUpdated version of the Burkholderia cepacia complex experimental strain panel.J Clin Microbiol2003;41:2797–810.1128/JCM.41.6.2797-2798.200312791937CunhaMV, LeitaoJH, MahenthiralingamE, VandammeP, LitoL, BarretoC, Molecular analysis of Burkholderia cepacia complex isolates from a Portuguese cystic fibrosis center: a 7-year study.J Clin Microbiol2003;41:4113–2010.1128/JCM.41.9.4113-4120.200312958234CoenyeT, SpilkerT, Van SchoorA, LiPumaJJ, VandammePRecovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe.Thorax2004;59:952–410.1136/thx.2003.01981015516470VandammeP, MahenthiralingamE, HolmesB, CoenyeT, HosteB, De VosP, Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV).J Clin Microbiol2000;38:1042–710698993